Investors
May 11, 2026
Taipei, Taiwan, 11 May 2026 — Lotus Pharmaceutical (1795:TT; “Lotus” or “the Company”), a multinational pharmaceutical company, announced its audited financial results for the first quarter ended March 31 2026, deliverin...
Historical News
All Years
All Category
303 Results
Lotus Pharmaceutical Delivered Record Quarterly High Revenue in First Quarter 2026
Investors
May 11, 2026
Taipei, Taiwan, 11 May 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for April 2026 of NT$3,086 million, representing...
Business
May 4, 2026
Taipei, Taiwan, 4 May 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced the successful global launch of its Nintedanib soft gel capsules (100mg and 150m...
Investors
Apr 10, 2026
Taipei, Taiwan, 10 April 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for March 2026 of NT$4,354 million, represent...
Business
Apr 8, 2026
Taipei, Taiwan, 08 April 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced that Zepzelca® (lurbinectedin), its licensed oncology product, has receiv...
Business
Apr 2, 2026
Taipei, Taiwan, 02 April 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that it has entered into an agreement to acquire Sandoz AG’s Philippines business. Subj...
Investors
Mar 12, 2026
Taipei, Taiwan, 12 March 2026 — Lotus Pharmaceuticals (1795:TT; “Lotus” or “the Company”), a multinational pharmaceutical company, announced its audited financial results for the full year 2025, delivering the seventh co...
Investors
Mar 10, 2026
Taipei, Taiwan, 10 March 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for February 2026 of NT$2,238 million, repres...
Business
Feb 24, 2026
Taipei, Taiwan, 24 February 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that it has filed a New Drug Application (“NDA”) under the 505(b)(2) regulator...
